Reality Check on Immune Thrombocytopenic Purpura
Market access for immune thrombocytopenic purpura treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 63% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In June 2019, the FDA gave an additional indication to Doptelet (avatrombopag) for the treatment of thrombocytopenia who have had an insufficient response to prior treatment
- Key Findings: Prior authorization is required by most payers for all products in the class. Most policies require documented diagnosis, platelet count and previous therapy with standard of care
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.